CXCL10 and systemic sclerosis: Blocking this pathway using JAK inhibitors is gaining momentum in the treatment of SSc.41, 42, 43 JAK inhibitors have the potential to block inflammatory and fibrotic pathways and have proven efficacies in other autoimmune diseases.44, 45, 46 Future research is needed to unravel the effect of these inhibitors on CXCL10 expression.